Other Inhibitors

FLT3-IN-19 (Comp 50) is a potent, selective inhibitor of FLT3, demonstrating an IC50 value of 0.213 nM, and is applicable in research pertaining to acute

RIOK2-IN-2 (8) functions as an inhibitor of RIOK2, exhibiting IC50 values of 3.02 μM in MKN-1 cells and 5.34 μM in MOLT4 cells [1].

BET-IN-1 is a bromodomain inhibitor extracted from patent WO/2013024104A1 (example 2, plC50: 6.0 - 7.0).

PD1-PDL1-IN 2 (ZE132) is a potent, selective inhibitor of PD-1/PD-L1, exhibiting significant anti-tumor activity in vivo. It enhances cytotoxic T-cell tumor infiltration and stimulates IL-2 expression, while also strongly inhibiting TGF-β [1] mRNA expression, showcasing its comprehensive immunotherapeutic potential.

Antitumor Photosensitizer-1 (Compound 8) is a potent photosensitizer with remarkable photodynamic anti-tumor properties and minimal skin photo-toxicity,

LT-540-717 (compound 32), a potent FLT3 inhibitor (IC50=0.62 nM), exhibits antiproliferative activity and effectively inhibits various acquired FLT3 mutations,

BPH-628 is a bioactive chemical.

Ifetroban sodium (BMS-180291), oral TXA2/PGH2 antagonist for researching heart, stroke, BP, thrombosis.

Ifetroban is a potent and selective TxA2/PGH2 receptor antagonist.

9,10-Phenanthrenequinone is an inhibitor of claudin-5/CLDN5, which induces apoptosis via an NO synthase/ROS-dependent mechanism. It also promotes caspase activation and DNA fragmentation while reducing CLDN5 expression and proteasome proteolysis, contributing to endothelial barrier dysfunction.